Categories: Wire Stories

AM Best Affirms Credit Ratings of Dah Sing Insurance Company (1976) Limited

HONG KONG–(BUSINESS WIRE)–AM Best has affirmed the Financial Strength Rating of A- (Excellent) and the Long-Term Issuer Credit Rating of �a-” of Dah Sing Insurance Company (1976) Limited (DSI) (Hong Kong). The outlook of these Credit Ratings (ratings) is stable.

The ratings reflect DSI’s balance sheet strength, which AM Best categorises as very strong, as well as its adequate operating performance, limited business profile and appropriate enterprise risk management.

The ratings also reflect the parental support from Dah Sing Financial Holdings Limited (DSFH) in terms of capital, brand recognition, business development, product distribution, risk management and operations.

AM Best expects DSI’s risk-adjusted capitalisation, as measured by Best’s Capital Adequacy Ratio (BCAR), to remain at the strongest level and supportive of the anticipated increases in asset and underwriting risks from business expansion over the short to intermediate term. Given its low net underwriting leverage ratio of approximately 54% and limited catastrophe exposure, DSI’s BCAR score is relatively stable in stressed scenarios. Following a large capital injection from DSFH in 2017, DSI has significantly expanded its investment portfolio over the past three years. The heightened investment risk is partially mitigated by the various constraints in investment policy and the diversity in its equity portfolio. Moreover, the company adopts an active and dynamic hedging strategy to mitigate short-term market risk. Other supportive factors to the balance sheet strength include organic capital growth from full profit retention and strong liquidity.

DSI has consistently delivered a profitable operating performance over the past five years, mainly driven by its favourable investment results, albeit partially offset by the relatively marginal and volatile underwriting performance.

As a small to medium-sized player in Hong Kong’s non-life insurance segment, DSI maintained a market share of approximately 1%, with a gross written premium of HKD 557.5 million (USD 71.6 million) in 2019. Going forward, the company intends to diversify its underwriting portfolio by expanding its inward reinsurance business, in particular in the casualty and financial lines, as well as direct business in the individual accident and health segment.

Offsetting rating factors include its high proportion of equity investments, which may generate volatility for the company’s capital and earnings. Other factors include the competitive operating environment and additional pressure on the company’s underwriting margin due to its increasing acquisition expenses.

While the company is well-positioned at its current rating levels, negative rating actions could occur if there is a material deterioration in the company’s risk-adjusted capitalisation or absolute size of capital and surplus, or a sustained unfavourable trend in operating performance. Negative rating actions are also possible if DSFH’s credit profile deteriorates materially, or if DSFH reduces the level of support it provides to DSI.

Ratings are communicated to rated entities prior to publication. Unless stated otherwise, the ratings were not amended subsequent to that communication.

This press release relates to Credit Ratings that have been published on AM Best’s website. For all rating information relating to the release and pertinent disclosures, including details of the office responsible for issuing each of the individual ratings referenced in this release, please see AM Best’s Recent Rating Activity web page. For additional information regarding the use and limitations of Credit Rating opinions, please view Guide to Best’s Credit Ratings. For information on the proper media use of Best’s Credit Ratings and AM Best press releases, please view Guide for Media – Proper Use of Best’s Credit Ratings and AM Best Rating Action Press Releases.

AM Best is a global credit rating agency, news publisher and data analytics provider specialising in the insurance industry. Headquartered in the United States, the company does business in over 100 countries with regional offices in New York, London, Amsterdam, Dubai, Hong Kong, Singapore and Mexico City. For more information, visit www.ambest.com.

Copyright © 2020 by A.M. Best Rating Services, Inc. and/or its affiliates. ALL RIGHTS RESERVED.

Contacts

June Wang

Associate Financial Analyst

+852 2827 3416

june.wang@ambest.com

James Chan

Associate Director

+852 2827 3418

james.chan@ambest.com

Christopher Sharkey

Manager, Public Relations

+1 908 439 2200, ext. 5159

christopher.sharkey@ambest.com

Jim Peavy

Director, Communications

+1 908 439 2200, ext. 5644

james.peavy@ambest.com

Alex

Recent Posts

Verdantis Appoints Kumar Gaurav Gupta as Chief Executive Officer

PRINCETON, N.J.--(BUSINESS WIRE)--Verdantis, a pioneering leader in AI-powered data solutions, proudly announces the appointment of…

46 mins ago

Galaxy Macau, The World-class Luxury Integrated Resort Comes to the “Experience Macao Roadshow in Jakarta”

Providing Exclusive and Unique Experiences to Indonesian Tourists MACAU SAR - Media OutReach Newswire -…

48 mins ago

SK hynix and HLDS Jointly Developed Tube T31 and Haechi H02 Win Red Dot Design Award and Exhibit at COMPUTEX

SEOUL, South Korea--(BUSINESS WIRE)--Leading semiconductor company SK hynix today announced that its stick-type SSD, the…

2 hours ago

NADclinic and Bontac Bio-Engineering (Shenzhen) Co., Ltd Announce Strategic Partnership to Evolve the Future of Global Wellness Through the Power of NAD+

LONDON--(BUSINESS WIRE)--NADclinic Group and Bontac Bio-Engineering (Shenzhen) Co., Ltd have officially entered into a dynamic…

2 hours ago

Drug Farm Announces IND Clearance by U.S. FDA Enabling Phase 1b Initiation for ALPK1 Selective Kinase Inhibitor, DF-003 in ROSAH Syndrome Patients

GUILFORD, Conn. & SHANGHAI--(BUSINESS WIRE)--Drug Farm announced today the U.S. Food and Drug Administration (FDA)…

2 hours ago

LiveSpo Pharma Emerges as Vietnam’s Pioneer at Vitafoods Europe 2024

Unveiling Groundbreaking Research and Product Development to Reduce Antibiotic Use in Digestive and Respiratory Care…

2 hours ago